title: Peptide receptor radiotherapy: a new option for the management of aggressive fibromatosis on behalf of the Italian Sarcoma Group.
abstract: The management of aggressive fibromatosis (AF) is problematic, and few options are available to patients unsuitable for surgery and resistant to external-beam radiation therapy (EBRT). We report on two patients with fast-growing recurrences of AF resistant to EBRT who obtained protracted clinical benefits with (90)Y-DOTATOC. (90)Y-DOTATOC should be further investigated in this setting.
authors.affiliation: Division of Medical Oncology, European of Oncology, Via Ripamonti, Milan, Italy. tommaso.de-pas@ieo.it
authors.forename: T
authors.initials: T
authors.lastname: De Pas
authors.forename: L
authors.initials: L
authors.lastname: Bodei
authors.forename: G
authors.initials: G
authors.lastname: Pelosi
authors.forename: F
authors.initials: F
authors.lastname: De Braud
authors.forename: G
authors.initials: G
authors.lastname: Villa
authors.forename: R
authors.initials: R
authors.lastname: Capanna
authors.forename: G
authors.initials: G
authors.lastname: Paganelli
mesh_terms: D000328:Adult; D005260:Female; D018222:Desmoid Tumors / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D015282:Octreotide / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D018714:Radiotherapy, Adjuvant / Q000379:methods*; D018000:Receptors, Peptide / Q000627:therapeutic use*; D012008:Recurrence; D012189:Retrospective Studies
chemical_list: D019275:Radiopharmaceuticals; D018000:Receptors, Peptide; D015282:Octreotide; C106246:Edotreotide